Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
B-ALL
MCID: BLY001
MIFTS: 50

B-Lymphoblastic Leukemia/lymphoma (B-ALL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for B-Lymphoblastic Leukemia/lymphoma

About this section

MalaCards integrated aliases for B-Lymphoblastic Leukemia/lymphoma:

Name: B-Lymphoblastic Leukemia/lymphoma 11 14 36
B Lymphoblastic Leukemia/lymphoma 11 71
B-All 11 53
Precursor B Lymphoblastic Lymphoma/leukemia 11
Lbl - [lymphoblastic Lymphoma] 33
Lymphoblastic B-Cell Lymphoma 33
Lymphoblastic Lymphoma, Nos 33
Common Precursor B All 33
B-Precursor Lymphoma 33
Pro-B All 33
C-All 33

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD11: 33


External Ids:

Disease Ontology 11 DOID:0080630
NCIt 49 C8936
SNOMED-CT 68 1162660006
UMLS 71 C0862030
Sources

Summaries for B-Lymphoblastic Leukemia/lymphoma

About this section

Disease Ontology: 11 A B-cell acute lymphoblastic leukemia that is characterized by the presence of too many B-cell lymphoblasts in the blood and bone marrow.

MalaCards based summary: B-Lymphoblastic Leukemia/lymphoma, also known as b lymphoblastic leukemia/lymphoma, is related to b-lymphoblastic leukemia/lymphoma with hypodiploidy and b-lymphoblastic leukemia/lymphoma with hyperdiploidy. An important gene associated with B-Lymphoblastic Leukemia/lymphoma is KMT2A (Lysine Methyltransferase 2A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Prednisolone phosphate and Prednisolone acetate have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and bone, and related phenotypes are homeostasis/metabolism and neoplasm
Sources

Related Diseases for B-Lymphoblastic Leukemia/lymphoma

About this section

Diseases in the B-Lymphoblastic Leukemia/lymphoma family:

B-Lymphoblastic Leukemia/lymphoma with T(9;22)(q34.1;q11.2) B-Lymphoblastic Leukemia/lymphoma with T
B-Lymphoblastic Leukemia/lymphoma with T(12;21)(p13.2;q22.1) B-Lymphoblastic Leukemia/lymphoma with T(1;19)(q23;p13.3)
B-Lymphoblastic Leukemia/lymphoma with T(5;14)(q31.1;q32.3)

Diseases related to B-Lymphoblastic Leukemia/lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 288)
# Related Disease Score Top Affiliating Genes
1 b-lymphoblastic leukemia/lymphoma with hypodiploidy 33.5 PBX1 ETV6
2 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 33.4 PBX1 ETV6
3 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 33.4 CDKN2A ABL1
4 b-lymphoblastic leukemia/lymphoma with bcr-abl1 33.3 PBX1 PAX5 KMT2A ETV6 ABL1
5 b-lymphoblastic leukemia/lymphoma with iamp21 33.2 PBX1 PAX5 ETV6 ABL1
6 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 32.7 FLT3 CDKN2A ABL1
7 lymphoma 31.1 PAX5 MYC DNTT CXCR5 CDKN2B CDKN2A
8 burkitt lymphoma 31.1 PAX5 MYC MME IL7 DNTT CXCR5
9 leukemia 30.8 PBX1 MYC MME KMT2A IL3 FLT3
10 hypereosinophilic syndrome 30.8 MPO IL3 ANPEP ABL1
11 follicular lymphoma 30.7 PAX5 MYC MME CXCR5 CDKN2A
12 acute myelomonocytic leukemia 30.6 MPO KMT2A FLT3 ETV6 DNTT
13 central nervous system lymphoma 30.6 PAX5 MYC MME CD19
14 lymphoblastic lymphoma 30.5 PAX5 MPO KMT2A DNTT CDKN2B
15 childhood acute lymphocytic leukemia 30.5 MME KMT2A FLT3 ETV6 CDKN2B CDKN2A
16 b-cell adult acute lymphocytic leukemia 30.5 PBX1 CD19 ANPEP ABL1
17 b-cell lymphoma 30.4 PAX5 MYC MME CXCR5 CDKN2B CDKN2A
18 lymphoma, hodgkin, classic 30.3 PAX5 IL7 IL3 CCR6
19 aplastic anemia 30.3 MYC MPO IL3 FLT3 CD34 CCR6
20 pancytopenia 30.3 MPO MME KMT2A IL3 FLT3 CD34
21 myeloproliferative neoplasm 30.3 MPO KMT2A IL3 FLT3 ETV6 CD34
22 lymphoplasmacytic lymphoma 30.2 PAX5 MME CD19
23 intellectual developmental disorder, autosomal dominant 29 30.2 PBX1 ABL1
24 diffuse large b-cell lymphoma 30.1 PEG10 PAX5 MYC MME CD19 CCR6
25 myeloma, multiple 30.1 PAX5 MYC IL7 IL3 FLT3 CXCR5
26 hematologic cancer 30.1 PAX5 KMT2A IL7 IL3 FLT3 ETV6
27 central nervous system leukemia 30.1 PBX1 MME KMT2A ETV6 CD34 CD19
28 childhood b-cell acute lymphoblastic leukemia 30.0 PAX5 ETV6
29 precursor t-cell acute lymphoblastic leukemia 30.0 MYC MPO KMT2A IL7 FLT3 ETV6
30 marginal zone b-cell lymphoma 30.0 PAX5 MYC MME CD19 CCR6
31 adult acute lymphocytic leukemia 30.0 PBX1 PAX5 MME KMT2A ETV6 CDKN2B
32 severe combined immunodeficiency 30.0 MYC IL7 IL3 FLT3 CD34 CD19
33 acute leukemia 29.9 PBX1 PAX5 MPO KMT2A IL7 IL3
34 childhood leukemia 29.9 PBX1 KMT2A FLT3 ETV6 CD34 CD19
35 leukemia, chronic myeloid 29.9 MYC MPO KMT2A IL3 FLT3 ETV6
36 mantle cell lymphoma 29.8 PAX5 MYC MME FLT3 CDKN2A CD34
37 thrombocytopenia 29.8 PAX5 IL7 IL3 FLT3 ETV6 CDKN2B
38 acute biphenotypic leukemia 29.8 PAX5 MPO MME KMT2A FLT3 ETV6
39 leukemia, acute lymphoblastic 29.5 PBX1 PAX5 MYC MPO MME KMT2A
40 leukemia, acute myeloid 29.4 PBX1 PAX5 MYC MPO MME KMT2A
41 myelodysplastic syndrome 29.4 MYC MPO KMT2A IL3 FLT3 ETV6
42 acute promyelocytic leukemia 29.3 MYC MPO KMT2A IL3 FLT3 ETV6
43 leukemia, chronic lymphocytic 29.1 PEG10 PAX5 MYC MME KMT2A IL7
44 b-lymphoblastic leukemia/lymphoma mll rearranged 11.9
45 b-lymphoblastic leukemia/lymphoma with etv6-runx1 11.9
46 b-lymphoblastic leukemia/lymphoma with tcf3-pbx1 11.8
47 b-lymphoblastic leukemia/lymphoma with il3-igh 11.8
48 b-lymphoblastic leukemia/lymphoma with t 11.7
49 b-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1) 11.6
50 b-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3) 11.5

Graphical network of the top 20 diseases related to B-Lymphoblastic Leukemia/lymphoma:



Diseases related to B-Lymphoblastic Leukemia/lymphoma
Sources

Symptoms & Phenotypes for B-Lymphoblastic Leukemia/lymphoma

About this section

MGI Mouse Phenotypes related to B-Lymphoblastic Leukemia/lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.27 ABL1 CCR6 CD19 CD34 CDKN2A CDKN2B
2 neoplasm MP:0002006 10.18 CD19 CD34 CDKN2A CDKN2B ETV6 FLT3
3 normal MP:0002873 10.16 ABL1 CCR6 CD19 CXCR5 DNTT ETV6
4 cellular MP:0005384 10.13 ABL1 CD19 CD34 CDKN2A CDKN2B CXCR5
5 immune system MP:0005387 10.13 ABL1 ANPEP CCR6 CD19 CD34 CDKN2A
6 endocrine/exocrine gland MP:0005379 10.02 ABL1 ANPEP CDKN2A CDKN2B ETV6 FLT3
7 liver/biliary system MP:0005370 10.01 ABL1 CD19 CDKN2A ETV6 KMT2A MME
8 no phenotypic analysis MP:0003012 9.98 CDKN2A CDKN2B ETV6 FLT3 IL7 KMT2A
9 hematopoietic system MP:0005397 9.91 ABL1 ANPEP CCR6 CD19 CD34 CDKN2A
10 integument MP:0010771 9.32 ANPEP CD19 CD34 CDKN2A CDKN2B ETV6
Sources

Drugs & Therapeutics for B-Lymphoblastic Leukemia/lymphoma

About this section

Drugs for B-Lymphoblastic Leukemia/lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
6
Ifosfamide Approved Phase 4 3778-73-2 3690
7
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
8
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
9
Palifosfamide Investigational Phase 4 31645-39-3 100427
10
Methylprednisolone Acetate Phase 4 584547
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
12
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
13
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
14
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
15
Mercaptopurine Approved Phase 3 50-44-2 667490
16
Tioguanine Approved Phase 3 154-42-7 2723601
17
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
18
Pegaspargase Approved, Investigational Phase 3 130167-69-0
19
Blinatumomab Approved, Investigational Phase 3 853426-35-4
20
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
21
Asparaginase Escherichia coli Approved, Investigational Phase 3 9015-68-3
22
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
23
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
24
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
25
Ichthammol Approved Phase 3 8029-68-3
26
Mitoxantrone Approved, Investigational Phase 3 70476-82-3, 65271-80-9 4212
27
Dasatinib Approved, Investigational Phase 3 302962-49-8 3062316
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
29
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 3 133585-56-5, 60-18-4, 556-02-5 1153 6057
30
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
31
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
32
Imatinib Mesylate Phase 3 220127-57-1
33 Neuroprotective Agents Phase 3
34 Protein Kinase Inhibitors Phase 3
35 Folic Acid Antagonists Phase 3
36 Vitamins Phase 3
37 Folate Phase 3
38 Antiviral Agents Phase 3
39 Vitamin B9 Phase 3
40 Anti-Infective Agents Phase 3
41 Trace Elements Phase 3
42 Antimetabolites Phase 3
43 Vitamin B Complex Phase 3
44 Antiemetics Phase 3
45 Calcium, Dietary Phase 3
46 Antidotes Phase 3
47 Gastrointestinal Agents Phase 3
48 Micronutrients Phase 3
49 Protective Agents Phase 3
50 Antibodies, Bispecific Phase 3

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
2 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
3 Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
4 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy Recruiting NCT03959085 Phase 3 Calaspargase Pegol-mknl;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
5 A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy) Recruiting NCT03914625 Phase 3 Asparaginase Erwinia chrysanthemi;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Mercaptopurine Oral Suspension;Methotrexate;Pegaspargase;Prednisolone;Prednisone;Thioguanine;Vincristine Sulfate
6 Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) Active, not recruiting NCT02101853 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Dexamethasone;Etoposide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Mitoxantrone;Mitoxantrone Hydrochloride;Pegaspargase;Therapeutic Hydrocortisone;Thioguanine;Vincristine;Vincristine Sulfate
7 Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy) Active, not recruiting NCT01190930 Phase 3 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
8 A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations Active, not recruiting NCT02883049 Phase 3 Clofarabine;Cyclophosphamide;Cytarabine;Dasatinib;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
9 Safety and Efficacy Evaluation of IM19 CAR-T Cells on Refractory or Relapsed B-ALL Patients Unknown status NCT03142646 Phase 1, Phase 2
10 Phase II, Multicenter, Open Label, Prospective to Evaluate Efficacy and Tolerance of a Chemoimmunotherapy With HyperCVAD or Vincristine/Dexamethasone Plus the Anti-CD22 Monovlonal Antobody Epratuzumab for the Treatment of Adult Relapsed/Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients : CHEPRALL Study, a GRAALL Study. Completed NCT01219816 Phase 2 Epratuzumab
11 An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed NCT01209286 Phase 2
12 Multicentre Study to Optimize Therapy of Burkitt's Leukemia (B-ALL) and Non-Hodgkin Lymphoma Completed NCT01290120 Phase 2 Chemotherapy-Rituximab combination
13 Small Noncleaved Cell (SNCC), Non-Hodgkin Lymphoma (NHL), Large Cell NHL (B-Cell) and B-Cell Acute Lymphoblastic Leukemia (B-ALL) Study II Completed NCT00187161 Phase 2 Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin
14 Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients Completed NCT03173417 Phase 1, Phase 2 fludarabine and cyclophosphamide
15 Multicenter Therapy Study for Children With Mature B-NHL or B-ALL With a Rituximab - Window Before Chemotherapy Completed NCT00324779 Phase 2
16 Study Evaluating Safety and Efficacy of CD19 and CD22 Targeted Prime CAR-T Cell in Patients With Relapsed/Refractory B-ALL Recruiting NCT04781634 Phase 1, Phase 2
17 An Investigator-initiated Trial to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of Relapsed/Refractory(r/r) CD19+ B-cell Acute Lymphoblastic Leukemia(B-ALL) Recruiting NCT05639179 Phase 1, Phase 2
18 Clinical Trial of CD19/CD22 Dual Target CAR-T Cells in the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Recruiting NCT04723901 Phase 1, Phase 2
19 Safety and Efficiency of Anti-CD19/CD22 Tandem Fully Human Chimeric Antigen Receptor (CAR)-Transduced T-cell Therapy for Pediatric and Young Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: a Single Centre, Non-randomised, Open Label Phase I-II Clinical Trial of Automatically Produced Cell Therapy Product MB-CAR-T19-22 Using CliniMACS Prodigy Recruiting NCT04499573 Phase 1, Phase 2 CD19/CD22 CAR-T
20 Phase 1/2b Trial of Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells Manufactured Using the CliniMACS Prodigy Platform for the Treatment of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL) Recruiting NCT05480449 Phase 1, Phase 2
21 A Phase II Study of CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients Previously Treated With Cell Therapy Recruiting NCT03902197 Phase 2
22 A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy Recruiting NCT03876769 Phase 2
23 A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) Recruiting NCT02981628 Phase 2 Cyclophosphamide;Cytarabine;Leucovorin Calcium;Methotrexate;Pegaspargase;Vincristine
24 Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. Recruiting NCT05049473 Phase 2 Rituximab;Methotrexate;Dexamethasone;Iphosphamid;Vincristine;Etoposide;Cytarabine;Cyclophosphamide;Doxorubicin;Vindesine;Hydrocortisone;Prednisone
25 A Phase 1/2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL). Recruiting NCT03743246 Phase 1, Phase 2 JCAR017;Lymphodepleting;Fludarabine;Cyclophosphamide
26 Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19) for Very High-Risk Subsets of B Cell Acute Lymphoblastic Leukemia (B-ALL) Recruiting NCT03792633 Phase 2
27 Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) Recruiting NCT03666000 Phase 1, Phase 2 Fludarabine;Cyclophosphamide
28 A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL Recruiting NCT05334823 Phase 2
29 A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse Recruiting NCT04546399 Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Etoposide;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
30 Phase 1/2 Dose Escalation and Preliminary Efficacy of CD19 Directed Car T Cells Generated Using The Miltenyi Clinimacs Prodigy System (UCD19 CarT) in Pediatric Patients With Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkins Lymphoma(B-NHL) Recruiting NCT04544592 Phase 1, Phase 2 CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
31 An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) Recruiting NCT05086315 Phase 1, Phase 2 SAR443579
32 Phase 2 Trial of CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL) Active, not recruiting NCT04276870 Phase 2
33 A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies Active, not recruiting NCT02328014 Phase 1, Phase 2 Acalabrutinib;ACP-319
34 Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) +/- Rituximab (R) + Tafasitamab-cxix for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative (Ph-) B-cell Lymphoblastic Lymphoma/Leukemia (B-ALL) Not yet recruiting NCT05453500 Phase 2 Cyclophosphamide;Doxorubicin;Etoposide;Prednisone;Vincristine
35 A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL) Terminated NCT02129062 Phase 2 Ibrutinib
36 A Phase IIa, Single-arm, Open-label Study of MOR00208, a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) Terminated NCT01685021 Phase 2 MOR00208 (formerly Xmab5574)
37 An Open-label, First-in-human, Dose Escalation Study of SAR440234 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), or High Risk Myelodysplasia (HR-MDS) Terminated NCT03594955 Phase 1, Phase 2 SAR440234
38 An Investigator-initiated Trial to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of Relapsed/Refractory(r/r) CD19+ B-cell Acute Lymphoblastic Leukemia(B-ALL) Withdrawn NCT05571540 Phase 1, Phase 2
39 Randomized Phase II Study Evaluating the Efficacy of 90Yttrium-epratuzumab Tetraxetan Radioimmunotherapy in Adults With CD22+ Relapsed/Refractory B-ALL Withdrawn NCT02844530 Phase 2 90Y-epratuzumab tetraxetan;chemotherapy/ immunotherapy
40 A Multi-Center, Open-Label Phase 1b/2 Study of Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Adult Patients With Relapsed/Refractory B Lineage Acute Lymphoblastic Leukemia (B-ALL) Withdrawn NCT03851081 Phase 1, Phase 2 Vincristine Sulfate Liposome
41 Phase I Study of the Safety and Efficacy of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL) Unknown status NCT03671460 Phase 1
42 Phase I Study of the Safety and Efficacy of CD19-CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL) Unknown status NCT03574168 Phase 1
43 Phase I, Open Label, Dose-escalation Study Followed by a Safety Expansion Part to Evaluate the Safety, Expansion and Persistence of a Single Dose of UCART19 (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor), Administered Intravenously in Patients With Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukaemia (B-ALL) Completed NCT02746952 Phase 1
44 A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL Completed NCT04888468 Phase 1
45 Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies Recruiting NCT04088890 Phase 1 Fludarabine;Cyclophosphamide;CD22 CAR
46 IIT2017-05-MERIN-BLINHMCT: Blinatumomab Plus HLA-Mismatched Cellular Therapy (HMCT) for Relapsed/Refractory CD19+ ALL Recruiting NCT03751709 Phase 1 Blinatumomab
47 Safety and Efficacy Study of Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies Recruiting NCT05513612 Phase 1 Fludarabine;Cyclophosphamide
48 CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) Recruiting NCT04318678 Phase 1 CD123-CAR T;Cyclophosphamide;Fludarabine;Mesna;Rituximab
49 A Single-arm, Open-label Phase I Study of CAR-T-19 (Anti CD19 scFv Chimeric Antigen Receptor T) Cells for Patients With CD19-positive Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia Under The Age of 25 Recruiting NCT05270772 Phase 1
50 A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies Recruiting NCT05397496 Phase 1

Search NIH Clinical Center for B-Lymphoblastic Leukemia/lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Lymphoblastic Leukemia/lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for B-Lymphoblastic Leukemia/lymphoma:
Blood stem cell transplantation for hematological diseases
Embryonic/Adult Cultured Cells Related to B-Lymphoblastic Leukemia/lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)
Sources

Genetic Tests for B-Lymphoblastic Leukemia/lymphoma

About this section
Sources

Anatomical Context for B-Lymphoblastic Leukemia/lymphoma

About this section

Organs/tissues related to B-Lymphoblastic Leukemia/lymphoma:

MalaCards : Bone Marrow, T Cells, Bone, Myeloid, Liver, Lymph Node, Spinal Cord
Sources

Publications for B-Lymphoblastic Leukemia/lymphoma

About this section

Articles related to B-Lymphoblastic Leukemia/lymphoma:

(show top 50) (show all 13216)
# Title Authors PMID Year
1
Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. 53 62
20160164 2010
2
[Prognostic significance of TEL/AML1 rearrangement and its additional genetic changes in Korean childhood precursor B-acute lymphoblastic leukemia]. 53 62
20197715 2010
3
ABL1 gene deletion without BCR/ABL1 rearrangement in a young adolescent with precursor B-cell acute lymphoblastic leukemia: clinical study and literature review. 53 62
20082857 2010
4
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 53 62
20023257 2010
5
Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. 53 62
19837270 2009
6
[Characteristics of fusion gene and immunophenotype in MLL gene rearrangement positive childhood acute lymphoblastic leukemia]. 53 62
19840468 2009
7
Very early onset of an acute myeloid leukemia in an adult patient with B-cell lymphoblastic leukemia. 53 62
19143872 2009
8
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. 53 62
18923441 2009
9
[Gene expression profile of human TGF-beta signal transduction pathway of B cell type acute lymphocytic leukemia]. 53 62
18718051 2008
10
Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia. 53 62
17434163 2007
11
[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. 53 62
17430665 2007
12
Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome. 53 62
17652839 2007
13
CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. 53 62
17082584 2006
14
Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study. 53 62
16938666 2006
15
Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. 53 62
16939815 2006
16
Chemokine receptor expression and function in childhood acute lymphoblastic leukemia of B-lineage. 53 62
16118018 2006
17
[Expression of the transcription factor PAX5 in childhood acute leukemic cells]. 53 62
16584581 2006
18
Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18). 53 62
16809887 2006
19
Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia. 53 62
16234090 2005
20
[Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry]. 53 62
16185473 2005
21
Interphase FISH to detect PBX1/E2A fusion resulting from the der(19)t(1;19)(q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia. 53 62
15801954 2005
22
[CXCR4 expression in B-lineage acute lymphocyte leukemia and its significance]. 53 62
15363127 2004
23
PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia. 53 62
16225771 2004
24
Mature B-cell acute lymphoblastic leukemia with t(9;11) translocation: a distinct subset of B-cell acute lymphoblastic leukemia. 53 62
15098014 2004
25
Is B-lineage acute lymphoblastic leukemia with a mature phenotype and l1 morphology a precursor B-lymphoblastic leukemia/lymphoma or Burkitt leukemia/lymphoma? 53 62
14521459 2003
26
[Analysis of immunophenotype of B-lineage acute lymphoblastic leukemia cells by 4-color flow cytometry]. 53 62
12744734 2003
27
[Immunophenotypic features of bcr/abl fusion transcript-positive B-lineage acute lymphoblast leukemia]. 53 62
12744735 2003
28
Analysis of p16 gene mutations and deletions in childhood acute lymphoblastic leukemias. 53 62
12870051 2003
29
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. 53 62
12393484 2003
30
Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones. 53 62
11697497 2001
31
Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones. 53 62
11699224 2001
32
Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. 53 62
11337015 2001
33
Differential expression of chemokine receptors in B cell malignancies. 53 62
11368435 2001
34
Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. 53 62
11237064 2001
35
Shifts in expression of immunological cell markers in relapsed acute leukemia. 53 62
11583283 2001
36
[Classification of acute leukemias according to the first latin-american consensus conference for the immunophenotyping of leukemias]. 53 62
11195181 2000
37
Expression of adhesion molecules in childhood B-lineage-cell neoplasms. 53 62
10979212 2000
38
Acute lymphoblastic leukaemia: correlation between morphological/immunohistochemical and molecular biological findings in bone marrow biopsy specimens. 53 62
10889907 2000
39
Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. 53 62
10634644 2000
40
[Homozygous deletion and methylation of p16 and p15 gene in acute leukemia]. 53 62
11721412 1999
41
Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. 53 62
10419905 1999
42
p16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. 53 62
10360377 1999
43
Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. 53 62
10233379 1999
44
Myeloperoxidase gene expression in infant leukemia: a Pediatric Oncology Group Study. 53 62
9638984 1998
45
Comparison of the effects of AcSDKP, thymosin beta4, macrophage inflammatory protein 1alpha and transforming growth factor beta on human leukemic cells. 53 62
9477130 1997
46
Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. 53 62
9399648 1997
47
C-kit receptors in childhood malignant lymphoblastic cells. 53 62
9168431 1997
48
Application of long PCR to detect t(8;14)(q24;q32) translocations in childhood Burkitt's lymphoma and B-ALL. 53 62
9187426 1997
49
Coexpression of cell-surface immunoglobulin (sIg), terminal deoxynucleotidyl transferase (TdT) and recombination activating gene 1 (RAG-1): two cases and derived cell lines. 53 62
8683996 1996
50
Heterogeneity of B lineage acute lymphoblastic leukemias (B-ALL) with regard to their in vitro spontaneous proliferation, growth factor response and BCL-2 expression. 53 62
8726408 1996
Sources

Variations for B-Lymphoblastic Leukemia/lymphoma

About this section
Sources

Expression for B-Lymphoblastic Leukemia/lymphoma

About this section
Search GEO for disease gene expression data for B-Lymphoblastic Leukemia/lymphoma.
Sources

Pathways for B-Lymphoblastic Leukemia/lymphoma

About this section

Pathways related to B-Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.73 ABL1 ANPEP CCR6 CD19 CD34 FLT3
2
ERK Signaling 64
Show member pathways
 13.62 MYC IL7 IL3 FLT3 CXCR5 CDKN2B
3
Signal Transduction 66
13.59 PBX1 MYC IL3 FLT3 CXCR5 CDKN2B
4
PI3K-Akt signaling pathway 74
Show member pathways
 12.77 MYC IL7 IL3 FLT3 CD19
5
Mitotic G1 phase and G1/S transition 66
Show member pathways
 12.3 MYC CDKN2B CDKN2A ABL1
6
NF-kappaB Signaling 3
12.21 CD19 CD34 CXCR5 IL3 MPO PAX5
7
Cell cycle 74
Show member pathways
 12.02 MYC CDKN2B CDKN2A ABL1
8
Senescence and autophagy in cancer 74
11.76 KMT2A IL3 CDKN2A
9
Extrafollicular B cell activation by SARS-CoV-2 74
11.54 CD19 CXCR5 PAX5
10
Innate Lymphoid Cells Differentiation 65
11.53 IL7 CXCR5 CD34 CCR6
11
Validated targets of C-MYC transcriptional repression 61
11.45 MYC DNTT CDKN2B
12
Dendritic Cells Developmental Lineage Pathway 65
11.43 MME FLT3 CD34 CD19
13
C-MYB transcription factor network 61
11.34 PAX5 MYC MPO CDKN2A CD34 ANPEP
14
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.29 MPO MME IL7 IL3 FLT3 CD34
15
Inhibition of Ribosome Biogenesis by p14(ARF) 64
10.92 MYC CDKN2A ABL1
16
TP53 network 74
Show member pathways
 10.85 MYC CDKN2A ABL1
17
RUNX1 regulates transcription of genes involved in BCR signaling 66
Show member pathways
 10.58 PAX5 IL3
Sources

GO Terms for B-Lymphoblastic Leukemia/lymphoma

About this section

Biological processes related to B-Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 9.86 PAX5 MPO MME CDKN2B
2 cellular senescence GO:0090398 9.8 CDKN2B CDKN2A ABL1
3 B cell proliferation involved in immune response GO:0002322 9.46 CD19 ABL1
4 embryonic hemopoiesis GO:0035162 9.43 PBX1 KMT2A IL3
5 spleen development GO:0048536 9.23 PBX1 KMT2A CDKN2B ABL1
Sources

Sources for B-Lymphoblastic Leukemia/lymphoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....